9350 Kirby Drive
Suite 300
Houston, TX 77054
United States
713 400 6400
https://markertherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 370.36k | N/A | 1980 |
Ms. Elizabeth Donnelly | Director of Administration | N/A | N/A | N/A |
Dr. Maria-Bernadette Madel | Director of Corporate Operations & External Communications | N/A | N/A | 1990 |
Mr. Edmund Cheung | Vice President of Human Resources | N/A | N/A | N/A |
Dr. Nadia Agopyan Ph.D. | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
Dr. Monic Stuart M.D. | Chief Medical Officer | N/A | N/A | N/A |
Patricia Allison | Head of Clinical Operations | N/A | N/A | N/A |
Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology & Virology | N/A | N/A | N/A |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.